A new modified version of the SARS-CoV-2 spike protein has a 10-fold higher expression rate in cell cultures than an earlier version that forms the basis of some candidates currently in clinical trials. Vaccine manufacturers could swap in the new version and produce vaccine doses at much higher rates, researchers say.
from Top Health News -- ScienceDaily https://ift.tt/3jzH35j
Subscribe to:
Post Comments (Atom)
Omicron has cast a shadow of uncertainty on growth outlook: IndiGo CEO
However, the airline is stronger now when compared to situation in 2020 during the first wave of the pandemic, says Ronojoy Dutta from Com...
-
While sales to original equipment manufacturers declined 16.3% year on year in FY20, the replacement market sales declined by a modest 2.6% ...
-
India's passenger vehicle sales are expected to grow between 3-5 percent in the current fiscal year, after expanding at the slowest pace...
-
The earnings momentum has been quite resilient and the policy momentum quite focused towards improving the infrastructure and attractiveness...
No comments:
Post a Comment